GTX (GTXI) Raised to “Hold” at ValuEngine

GTX (NASDAQ:GTXI) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

Several other research firms have also commented on GTXI. Zacks Investment Research lowered GTX from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. BidaskClub upgraded GTX from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 26th. Stifel Nicolaus started coverage on GTX in a research note on Thursday, November 9th. They issued a “buy” rating for the company. Finally, Robert W. Baird started coverage on GTX in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 price objective for the company. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $17.00.

Shares of GTX (NASDAQ:GTXI) opened at $14.90 on Wednesday. GTX has a 12 month low of $2.73 and a 12 month high of $15.81.

GTX (NASDAQ:GTXI) last posted its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.25). research analysts anticipate that GTX will post -1.61 EPS for the current fiscal year.

In related news, insider Jason T. Shackelford sold 3,090 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $35,009.70. Following the completion of the transaction, the insider now owns 31,111 shares of the company’s stock, valued at approximately $352,487.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc Steven Hanover sold 7,309 shares of the company’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $82,810.97. Following the completion of the transaction, the chief executive officer now directly owns 129,990 shares of the company’s stock, valued at approximately $1,472,786.70. The disclosure for this sale can be found here. Insiders sold a total of 15,364 shares of company stock valued at $174,074 in the last ninety days. 41.20% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of GTXI. Abingworth LLP bought a new position in GTX in the 3rd quarter worth $2,781,000. Caxton Corp bought a new position in GTX in the 3rd quarter worth $531,000. Finally, Bank of New York Mellon Corp bought a new position in GTX in the 2nd quarter worth $124,000. 11.54% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2018/02/09/gtx-gtxi-raised-to-hold-at-valuengine.html.

About GTX

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply